Horizon Therapeutics Public Limited Company
Symbol: HZNP
NASDAQ
116.3
USDMarknadspris idag
62.1155
P/E-tal
0.5721
PEG-kvot
26.63B
MRK Aktiekapital
- 0.00%
DIV Avkastning
{{företagets_namn}} (HZNP) Finansiella rapporter
Balansräkning
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 9289.14 | 2352.8 | 1580.3 | 2079.9 | |||||||||||||||
balance-sheet.row.short-term-investments | 114.75 | 28.2 | 26.5 | 18.4 | |||||||||||||||
balance-sheet.row.net-receivables | 2670.21 | 676.3 | 632.8 | 659.7 | |||||||||||||||
balance-sheet.row.inventory | 694.64 | 169.6 | 225.7 | 75.3 | |||||||||||||||
balance-sheet.row.other-current-assets | 1549.86 | 449.3 | 360.9 | 255.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 14589.66 | 3652.8 | 2799.8 | 3070.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 1376.4 | 340.5 | 292.3 | 189 | |||||||||||||||
balance-sheet.row.goodwill | 4042.15 | 1010.5 | 1066.7 | 413.7 | |||||||||||||||
balance-sheet.row.intangible-assets | 13725.2 | 3474.8 | 3840.1 | 1783 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 17767.35 | 4485.3 | 4906.8 | 2196.6 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.tax-assets | 1842.66 | 431.8 | 538.1 | 560.8 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 858.6 | 204.1 | 140.7 | 55.7 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 21845.01 | 5461.8 | 5878 | 3002.2 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 36434.67 | 9114.6 | 8677.7 | 6072.6 | |||||||||||||||
balance-sheet.row.account-payables | 350.07 | 155.8 | 30.1 | 37.7 | |||||||||||||||
balance-sheet.row.short-term-debt | 64 | 16 | 16 | 0 | |||||||||||||||
balance-sheet.row.tax-payables | 172.07 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 10181.67 | 2546.8 | 2555.2 | 1003.4 | |||||||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 1263.5 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 3198.24 | 777.3 | 840.4 | 838 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 12309.97 | 3093.3 | 3118.8 | 1171.5 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-liab | 15922.29 | 4042.4 | 4005.3 | 2047.3 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0.09 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.retained-earnings | 2612.75 | 590 | 318.6 | -215.9 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 48.28 | 12.5 | -15 | -0.1 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 17851.26 | 4469.6 | 4368.8 | 4241.4 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 20512.38 | 5072.2 | 4672.4 | 4025.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 36434.67 | 9114.6 | 8677.7 | 6072.6 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-equity | 20512.38 | 5072.2 | 4672.4 | 4025.4 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 36434.67 | - | - | - | |||||||||||||||
Total Investments | 114.75 | 28.2 | 26.5 | 18.4 | |||||||||||||||
balance-sheet.row.total-debt | 10245.67 | 2562.8 | 2571.2 | 1003.4 | |||||||||||||||
balance-sheet.row.net-debt | 986.05 | 210 | 990.9 | -1076.5 |
Kassaflödesanalys
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 438 | 521.5 | 534.5 | 389.8 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 389 | 390.4 | 353.8 | 279.5 | |||||||||||||||
cash-flows.row.deferred-income-tax | -39.11 | 49.8 | -101 | -33.5 | |||||||||||||||
cash-flows.row.stock-based-compensation | 208.04 | 182.1 | 219.1 | 146.6 | |||||||||||||||
cash-flows.row.change-in-working-capital | -5.32 | -12 | -61.7 | -345.7 | |||||||||||||||
cash-flows.row.account-receivables | -44.08 | -43.5 | 34.8 | -251.2 | |||||||||||||||
cash-flows.row.inventory | 33.32 | 56.1 | 1.3 | -21.5 | |||||||||||||||
cash-flows.row.account-payables | 63.98 | 122.2 | -12.2 | 16 | |||||||||||||||
cash-flows.row.other-working-capital | -58.54 | -146.9 | -85.6 | -89.1 | |||||||||||||||
cash-flows.row.other-non-cash-items | 50.03 | 126 | 90.7 | 118.9 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 1040.64 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -134.52 | -126.3 | -126.2 | -199.9 | |||||||||||||||
cash-flows.row.acquisitions-net | 28.45 | -3.1 | -2845.3 | -262.3 | |||||||||||||||
cash-flows.row.purchases-of-investments | -8.57 | -9.2 | -24.7 | -13.3 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0.22 | 4.6 | -49.6 | -30 | |||||||||||||||
cash-flows.row.other-investing-activites | -28.45 | 0 | 51.6 | 41.4 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | -142.87 | -134 | -2994.1 | -464.1 | |||||||||||||||
cash-flows.row.debt-repayment | -16 | -16 | -12 | -1.7 | |||||||||||||||
cash-flows.row.common-stock-issued | 34.99 | 30.3 | 0 | 919.8 | |||||||||||||||
cash-flows.row.common-stock-repurchased | -250.08 | -250.1 | 0 | 0 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.other-financing-activites | -103.35 | -112.2 | 1482.1 | -13.5 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -334.43 | -348 | 1470.1 | 904.6 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 8.77 | -2.5 | -10.6 | 7.2 | |||||||||||||||
cash-flows.row.net-change-in-cash | 572.11 | 773.4 | -499.3 | 1003.4 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 9278.67 | 2357.6 | 1584.2 | 2083.5 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 8706.56 | 1584.2 | 2083.5 | 1080 | |||||||||||||||
cash-flows.row.operating-cash-flow | 1040.64 | 1257.8 | 1035.3 | 555.7 | |||||||||||||||
cash-flows.row.capital-expenditure | -134.52 | -126.3 | -126.2 | -199.9 | |||||||||||||||
cash-flows.row.free-cash-flow | 906.13 | 1131.6 | 909.1 | 355.8 |
Resultaträkning rad
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 3644.41 | 3629 | 3226.4 | 2200.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 903.44 | 920.2 | 794.5 | 532.7 | |||||||||||||||
income-statement-row.row.gross-profit | 2740.97 | 2708.8 | 2431.9 | 1667.7 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 515.77 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 770.1 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0.4 | -5.6 | 1.8 | 3.4 | |||||||||||||||
income-statement-row.row.operating-expenses | 2173.34 | 1979 | 1878.4 | 1182.6 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 3076.78 | 2899.2 | 2672.9 | 1715.3 | |||||||||||||||
income-statement-row.row.interest-income | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.interest-expense | 68.68 | 83.7 | 81.1 | 59.6 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | -55.41 | -90.5 | -80.3 | -88.4 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0.4 | -5.6 | 1.8 | 3.4 | |||||||||||||||
income-statement-row.row.total-operating-expenses | -55.41 | -90.5 | -80.3 | -88.4 | |||||||||||||||
income-statement-row.row.interest-expense | 68.68 | 83.7 | 81.1 | 59.6 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 441.47 | 497.2 | 365.9 | 278 | |||||||||||||||
income-statement-row.row.ebitda-caps | 957.03 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 513.37 | 617.4 | 543.1 | 490 | |||||||||||||||
income-statement-row.row.income-before-tax | 443.86 | 526.9 | 462.8 | 401.6 | |||||||||||||||
income-statement-row.row.income-tax-expense | 5.86 | 5.5 | -71.7 | 11.8 | |||||||||||||||
income-statement-row.row.net-income | 438 | 521.5 | 534.5 | 389.8 |
Ofta ställda frågor
Vad är Horizon Therapeutics Public Limited Company (HZNP) totala tillgångar?
Horizon Therapeutics Public Limited Company (HZNP) totala tillgångar är 9114616000.000.
Vad är företagets årliga omsättning?
Den årliga intäkten är 1777018000.000.
Vad är företagets vinstmarginal?
Företagets vinstmarginal är 0.752.
Vad är företagets fria kassaflöde?
Fritt kassaflöde är 3.873.
Vad är företagets nettovinstmarginal?
Nettovinstmarginalen är 0.120.
Vad är företagets totala intäkter?
Totala intäkter är 0.141.
Vad är Horizon Therapeutics Public Limited Company (HZNP) nettovinst (nettoinkomst)?
Nettovinst (nettoinkomst) är 521482000.000.
Vad är företagets totala skuldsättning?
Den totala skulden är 2562837000.000.
Vad är rörelsens kostnader?
Rörelsens kostnader är 1979014000.000.
Vad är företagets kassaflöde?
Företagets kassa är 2464623000.000.